AU2021247163A1 - Multilamellar RNA nanoparticle vaccine against SARS-CoV-2 - Google Patents

Multilamellar RNA nanoparticle vaccine against SARS-CoV-2 Download PDF

Info

Publication number
AU2021247163A1
AU2021247163A1 AU2021247163A AU2021247163A AU2021247163A1 AU 2021247163 A1 AU2021247163 A1 AU 2021247163A1 AU 2021247163 A AU2021247163 A AU 2021247163A AU 2021247163 A AU2021247163 A AU 2021247163A AU 2021247163 A1 AU2021247163 A1 AU 2021247163A1
Authority
AU
Australia
Prior art keywords
rna
nanoparticle
nps
nucleic acid
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021247163A
Other languages
English (en)
Inventor
Paul Antonio CASTILLO CARO
Noah Thomas JONES
Hector Ruben Mendez-Gomez
Duane A. Mitchell
Elias SAYOUR
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Florida Research Foundation Inc
Original Assignee
University of Florida Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Florida Research Foundation Inc filed Critical University of Florida Research Foundation Inc
Publication of AU2021247163A1 publication Critical patent/AU2021247163A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2021247163A 2020-04-01 2021-03-31 Multilamellar RNA nanoparticle vaccine against SARS-CoV-2 Pending AU2021247163A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063003766P 2020-04-01 2020-04-01
US63/003,766 2020-04-01
US202063022999P 2020-05-11 2020-05-11
US63/022,999 2020-05-11
US202063128600P 2020-12-21 2020-12-21
US63/128,600 2020-12-21
PCT/US2021/025222 WO2021202772A1 (en) 2020-04-01 2021-03-31 Multilamellar rna nanoparticle vaccine against sars-cov-2

Publications (1)

Publication Number Publication Date
AU2021247163A1 true AU2021247163A1 (en) 2022-10-20

Family

ID=75625672

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021247163A Pending AU2021247163A1 (en) 2020-04-01 2021-03-31 Multilamellar RNA nanoparticle vaccine against SARS-CoV-2

Country Status (6)

Country Link
US (1) US20230226169A1 (https=)
EP (1) EP4126030A1 (https=)
JP (1) JP2023520506A (https=)
AU (1) AU2021247163A1 (https=)
CA (1) CA3174187A1 (https=)
WO (1) WO2021202772A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7783628B2 (ja) * 2019-07-19 2025-12-10 ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド 多層ｒｎａナノ粒子
IL297419B2 (en) 2020-04-22 2025-02-01 BioNTech SE Coronavirus vaccine
WO2022008973A2 (en) * 2020-07-10 2022-01-13 Covid Diagnostics Ltd. Compositions, methods, and systems for detecting immune response
JP2023536962A (ja) * 2020-08-06 2023-08-30 エフ． ホフマン－ラ ロシュ アーゲー 重症急性呼吸器症候群コロナウイルス２（ｓａｒｓ－２）、インフルエンザａ及びインフルエンザｂの検出のための組成物及び方法
IL303434A (en) * 2020-12-07 2023-08-01 Tufts College Lipidoid preparations and methods of using them
US12186387B2 (en) 2021-11-29 2025-01-07 BioNTech SE Coronavirus vaccine
WO2024010686A2 (en) * 2022-06-20 2024-01-11 The Trustees Of Columbia University In The City Of New York Vaccine tissue assays
WO2024002985A1 (en) 2022-06-26 2024-01-04 BioNTech SE Coronavirus vaccine
WO2025089649A1 (ko) * 2023-10-26 2025-05-01 주식회사 차백신연구소 양이온성 리포좀을 포함하는 핵산 전달용 조성물 및 그의 용도

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
KR101766408B1 (ko) 2009-06-10 2017-08-10 알닐람 파마슈티칼스 인코포레이티드 향상된 지질 조성물
US8802863B2 (en) 2010-05-24 2014-08-12 Sirna Therapeutics, Inc. Amino alcohol cationic lipids for oligonucleotide delivery
DK2575767T3 (en) 2010-06-04 2017-03-13 Sirna Therapeutics Inc HOWEVER UNKNOWN LOW MOLECULAR CATIONIC LIPIDS TO PROCESS OIGONUCLEOTIDES
CA2841047A1 (en) * 2011-07-06 2013-01-10 Novartis Ag Immunogenic compositions and uses thereof
EP2858679B2 (en) * 2012-06-08 2024-06-05 Translate Bio, Inc. Pulmonary delivery of mrna to non-lung target cells
CN107073028A (zh) * 2013-12-13 2017-08-18 南洋理工大学 多层纳米颗粒及其制作方法和使用方法
US20220233568A1 (en) * 2017-10-19 2022-07-28 Curevac Ag Novel artificial nucleic acid molecules
US10979132B2 (en) * 2018-08-10 2021-04-13 Qualcomm Incorporated Organization of inter-relay discovery reference signals
JP7783628B2 (ja) * 2019-07-19 2025-12-10 ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド 多層ｒｎａナノ粒子
US12194089B2 (en) * 2020-02-04 2025-01-14 CureVac SE Coronavirus vaccine

Also Published As

Publication number Publication date
EP4126030A1 (en) 2023-02-08
CA3174187A1 (en) 2021-10-07
JP2023520506A (ja) 2023-05-17
US20230226169A1 (en) 2023-07-20
WO2021202772A1 (en) 2021-10-07

Similar Documents

Publication Publication Date Title
US20230226169A1 (en) Multilamellar rna nanoparticle vaccine against sars-cov-2
Mendez-Gomez et al. RNA aggregates harness the danger response for potent cancer immunotherapy
CN115697298A (zh) 脂质纳米颗粒
CN116133640A (zh) 脂质纳米颗粒
US12514930B2 (en) Methods of sensitizing tumors to treatment with immune checkpoint inhibitors
TW202327646A (zh) Rna分子
US20230346700A1 (en) Multilamellar RNA Nanoparticles and Methods of Sensitizing Tumors to Treatment with Immune Checkpoint Inhibitors
US20230096704A1 (en) Rna-loaded nanoparticles and use thereof for the treatment of cancer
AU2020316335B2 (en) Multilamellar RNA nanoparticles
WO2023147092A9 (en) Coronavirus vaccine
KR20210082186A (ko) 폐 염증 요법을 위한 나노담체
US20240238418A1 (en) Car t cell therapy method
CA3166934A1 (en) Rna-loaded nanoparticles and use thereof for the treatment of cancer
US12558407B2 (en) Compositions for treatment of diffuse intrinsic pontine glioma
WO2023196232A1 (en) Method of characterizing tumors
US20240299516A1 (en) Multilamellar rna nanoparticle vaccine against cancer
WO2025207807A1 (en) Ctc rna-loaded nanoparticles and use thereof for the treatment of cancer
WO2024263713A1 (en) Materials and methods of using proinsulin mrna nanoparticles
CN121197383A (zh) 多价埃博拉病毒广谱mRNA疫苗及其制备方法与应用
HK40112617A (zh) 诺如病毒疫苗及使用方法